The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05397470
Recruitment Status : Active, not recruiting
First Posted : May 31, 2022
Last Update Posted : March 12, 2024
Information provided by (Responsible Party):
Fulcrum Therapeutics